Related Experiment Video
Updated: Jun 26, 2025
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
Thyroid cancer prognostic biomarker ARL4A and its relationship with immune infiltration
Xiaoyong Han1, Jianping Liao1, Yaoping Zhou1
1Department of Otolaryngology, Linping District Hospital of Traditional Chinese Medicine Hangzhou 311100, Zhejiang, China.
Background:
Thyroid cancer (THCA) is a prevalent form of cancer with high rates of morbidity and mortality. The small GTPase ADP-ribosylation factor-like 4A (ARL4A) is integral to various cellular processes, including cytoskeletal restructuring, vesicular transport, cell migration, and neuronal development. However, the role of ARL4A as a clinical predictor, particularly its relation to immune cell infiltration in THCA, remains unclear.
Methods:
A combination of experimental studies and analysis of online databases was employed to investigate ARL4A expression in THCA. Clinical and pathological data from THCA patients were compiled for a comprehensive subgroup analysis. The Kaplan-Meier and Cox regression methods were utilized to evaluate the prognostic significance of ARL4A in THCA patients. Finally, the "Cancer Genome Atlas" was analyzed to explore the correlation between immune cell infiltration, ARL4A expression, and their joint impact on prognosis.
Results:
ARL4A exhibited low expression in THCA. An elevated ARL4A was associated with poor prognosis. Moreover, the expression of ARL4A was correlated with the age, gender, and pathological stage of THCA patients. Finally, ARL4A expression was found to be negatively correlated with immune cell infiltration and influenced the prognosis of patients through changes in the immune environment.
Conclusion:
ARL4A may serve as a potential biomarker for the diagnosis and treatment of THCA, impacting the prognosis of patients through the modulation of the immune microenvironment.
Insights
ADP-ribosylation factor-like 4A (ARL4A) is linked to thyroid cancer (THCA) prognosis. Low ARL4A expression correlates with poor outcomes and altered immune cell infiltration, suggesting its potential as a diagnostic biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Thyroid cancer (THCA) presents significant morbidity and mortality.
- ADP-ribosylation factor-like 4A (ARL4A) plays roles in cellular functions but its prognostic value in THCA is unknown.
- The relationship between ARL4A and immune cell infiltration in THCA requires elucidation.
Purpose of the Study:
- To investigate the expression and prognostic significance of ARL4A in thyroid cancer.
- To explore the correlation between ARL4A expression, immune cell infiltration, and patient outcomes in THCA.
- To determine if ARL4A can serve as a clinical predictor in THCA.
Main Methods:
- Analysis of ARL4A expression in THCA using experimental studies and public databases.
- Compilation of clinical and pathological data for subgroup analysis.
- Prognostic evaluation using Kaplan-Meier and Cox regression, with correlation analysis against immune infiltration via The Cancer Genome Atlas.
Main Results:
- ARL4A expression was found to be low in THCA tissues.
- Elevated ARL4A levels were associated with poorer prognosis and correlated with patient age, gender, and pathological stage.
- ARL4A expression showed a negative correlation with immune cell infiltration, indicating an impact on the immune microenvironment and patient prognosis.
Conclusions:
- ARL4A may function as a potential diagnostic and prognostic biomarker for thyroid cancer.
- ARL4A influences THCA prognosis by modulating the tumor immune microenvironment.
- Targeting ARL4A could offer new therapeutic strategies for thyroid cancer.
